Keyphrases
Phase II Study
100%
Moderate-to-severe Psoriasis
100%
Ustekinumab
100%
Ixekizumab
100%
Static Physician's Global Assessment
57%
Itch
28%
Dermatology Life Quality Index
28%
PASI 75
28%
PASI100
28%
Numerical Rating Scale
28%
Assessment Score
28%
Index Score
14%
Interleukin-17 (IL-17)
14%
Interleukin-23 (IL-23)
14%
IL-17 Inhibitors
14%
Safety Data
14%
British Association
14%
Confidence Interval
14%
Adverse Events
14%
4-point
14%
Safety Profile
14%
Dermatologist
14%
Response Rate
14%
Head-to-head Trials
14%
Efficacy Data
14%
Psoriasis Area
14%
Area Index
14%
Psoriasis Severity
14%
Severity Index
14%
Global Dermatology
14%
IL-23 Inhibitors
14%
Starting Dose
14%
High Response Rate
14%
Weight-based Dosing
14%
Visual Analog Pain Scale
14%
Psoriasis Pathogenesis
14%
Skin Pain
14%
Points Reduction
14%
Rating Changes
14%
Response Difference
14%
Medicine and Dentistry
Psoriasis
100%
Ustekinumab
100%
Ixekizumab
100%
Pruritus
28%
Dermatology Life Quality Index
28%
Numeric Rating Scale
28%
Interleukin 17
28%
Adverse Event
14%
Visual Analog Scale
14%
Interleukin 23
14%
Skin Pain
14%
Interleukin 12
14%
Dermatology
14%
Psoriasis Area and Severity Index
14%